629 related articles for article (PubMed ID: 21703997)
1. BCL9-2 promotes early stages of intestinal tumor progression.
Brembeck FH; Wiese M; Zatula N; Grigoryan T; Dai Y; Fritzmann J; Birchmeier W
Gastroenterology; 2011 Oct; 141(4):1359-70, 1370.e1-3. PubMed ID: 21703997
[TBL] [Abstract][Full Text] [Related]
2. ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression.
Shin HW; Choi H; So D; Kim YI; Cho K; Chung HJ; Lee KH; Chun YS; Cho CH; Kang GH; Kim WH; Park JW
Gastroenterology; 2014 Aug; 147(2):430-442.e8. PubMed ID: 24846398
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
[TBL] [Abstract][Full Text] [Related]
4. Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis.
Kress E; Skah S; Sirakov M; Nadjar J; Gadot N; Scoazec JY; Samarut J; Plateroti M
Gastroenterology; 2010 May; 138(5):1863-74. PubMed ID: 20114049
[TBL] [Abstract][Full Text] [Related]
5. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA
Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963
[TBL] [Abstract][Full Text] [Related]
6. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
7. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.
Adachi S; Jigami T; Yasui T; Nakano T; Ohwada S; Omori Y; Sugano S; Ohkawara B; Shibuya H; Nakamura T; Akiyama T
Cancer Res; 2004 Dec; 64(23):8496-501. PubMed ID: 15574752
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
Labbé E; Lock L; Letamendia A; Gorska AE; Gryfe R; Gallinger S; Moses HL; Attisano L
Cancer Res; 2007 Jan; 67(1):75-84. PubMed ID: 17210685
[TBL] [Abstract][Full Text] [Related]
9. Stromal Indian hedgehog signaling is required for intestinal adenoma formation in mice.
Büller NV; Rosekrans SL; Metcalfe C; Heijmans J; van Dop WA; Fessler E; Jansen M; Ahn C; Vermeulen JL; Westendorp BF; Robanus-Maandag EC; Offerhaus GJ; Medema JP; D'Haens GR; Wildenberg ME; de Sauvage FJ; Muncan V; van den Brink GR
Gastroenterology; 2015 Jan; 148(1):170-180.e6. PubMed ID: 25307863
[TBL] [Abstract][Full Text] [Related]
10. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
Ito K; Lim AC; Salto-Tellez M; Motoda L; Osato M; Chuang LS; Lee CW; Voon DC; Koo JK; Wang H; Fukamachi H; Ito Y
Cancer Cell; 2008 Sep; 14(3):226-37. PubMed ID: 18772112
[TBL] [Abstract][Full Text] [Related]
11. Wnt inhibitory factor-1: a candidate for a new player in tumorigenesis of intestinal epithelial cells.
Cebrat M; Strzadala L; Kisielow P
Cancer Lett; 2004 Mar; 206(1):107-13. PubMed ID: 15019166
[TBL] [Abstract][Full Text] [Related]
12. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.
Crawford HC; Fingleton BM; Rudolph-Owen LA; Goss KJ; Rubinfeld B; Polakis P; Matrisian LM
Oncogene; 1999 May; 18(18):2883-91. PubMed ID: 10362259
[TBL] [Abstract][Full Text] [Related]
13. The Intestinal Wnt/TCF Signature.
Van der Flier LG; Sabates-Bellver J; Oving I; Haegebarth A; De Palo M; Anti M; Van Gijn ME; Suijkerbuijk S; Van de Wetering M; Marra G; Clevers H
Gastroenterology; 2007 Feb; 132(2):628-32. PubMed ID: 17320548
[TBL] [Abstract][Full Text] [Related]
14. Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation.
Feng Y; Bommer GT; Zhai Y; Akyol A; Hinoi T; Winer I; Lin HV; Cadigan KM; Cho KR; Fearon ER
Cancer Res; 2007 Jan; 67(2):482-91. PubMed ID: 17234755
[TBL] [Abstract][Full Text] [Related]
15. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.
Zeilstra J; Joosten SP; Dokter M; Verwiel E; Spaargaren M; Pals ST
Cancer Res; 2008 May; 68(10):3655-61. PubMed ID: 18483247
[TBL] [Abstract][Full Text] [Related]
17. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice.
Musteanu M; Blaas L; Mair M; Schlederer M; Bilban M; Tauber S; Esterbauer H; Mueller M; Casanova E; Kenner L; Poli V; Eferl R
Gastroenterology; 2010 Mar; 138(3):1003-11.e1-5. PubMed ID: 19962983
[TBL] [Abstract][Full Text] [Related]
18. Foxf2 in intestinal fibroblasts reduces numbers of Lgr5(+) stem cells and adenoma formation by inhibiting Wnt signaling.
Nik AM; Reyahi A; Pontén F; Carlsson P
Gastroenterology; 2013 May; 144(5):1001-11. PubMed ID: 23376422
[TBL] [Abstract][Full Text] [Related]
19. Phases of canonical Wnt signaling during the development of mouse intestinal epithelium.
Kim BM; Mao J; Taketo MM; Shivdasani RA
Gastroenterology; 2007 Aug; 133(2):529-38. PubMed ID: 17681174
[TBL] [Abstract][Full Text] [Related]
20. The role of Pygo2 for Wnt/ß-catenin signaling activity during intestinal tumor initiation and progression.
Talla SB; Brembeck FH
Oncotarget; 2016 Dec; 7(49):80612-80632. PubMed ID: 27811361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
